PS
BMRN icon

Portfolio Solutions’s BioMarin Pharmaceuticals BMRN Stock Holding History

Portfolio Solutions’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-29
Closed -$2K – 46
2018
Q1 		$2K Hold
29
– – ﹤0.01% 191
2017
Q4 		$3K Hold
29
– – ﹤0.01% 171
2017
Q3 		$3K Hold
29
– – ﹤0.01% 166
2017
Q2 		$3K Hold
29
– – ﹤0.01% 154
2017
Q1 		$3K Buy
+29
New +$2.58K ﹤0.01% 180

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Portfolio Solutions's BMRN Position: Q2 2018 in Review

Portfolio Solutions sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2018, closing a stake of 29 shares — an estimated $2K sold.

Portfolio Solutions first reported a position in BMRN in Q1 2017 and held it in 5 quarters. The position peaked at $3K in Q4 2017. 448 funds tracked by Wall St. Rank hold BMRN as of Q2 2018.

  • Portfolio Solutions reported no remaining BioMarin Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Portfolio Solutions sold 29 BioMarin Pharmaceuticals shares in Q2 2018, an estimated $2K.
  • Portfolio Solutions first reported a position in BioMarin Pharmaceuticals in Q1 2017 and held it in 5 quarters.
  • Portfolio Solutions's BioMarin Pharmaceuticals position peaked at $3K in Q4 2017.
  • 448 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2018.

Based on Portfolio Solutions's 13F filing for Q2 2018, filed 13 Jul 2018.